We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00318162
Recruitment Status : Unknown
Verified April 2006 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : April 26, 2006
Last Update Posted : May 3, 2006
Sponsor:
Collaborator:
Jerusalem Institute for Child Development
Information provided by:
Hadassah Medical Organization

Brief Summary:
This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language.

Condition or disease Intervention/treatment Phase
Pervasive Developmental Disorder Drug: low dose naltrexone Phase 1 Phase 2

Detailed Description:
Fifty children aged three to six years will be recruited for the study. They will be randomly assigned to receive either LDN or placebo for two months after which the treatment groups will be switched over. Assessments of functioning will be obtained from a video-taped play session, and by parent and teacher questionnaires at baseline, after two months and after four months.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized Double-Blind Trial of Low-Dose Naltrexone for Children With PDD





Primary Outcome Measures :
  1. play observation
  2. Autism Behavior Checklist (ABC) questionnaire


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Years to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of PDD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318162


Contacts
Contact: David S Wilensky, MD 97227828142 davidvil@012.net.il

Locations
Israel
Jerusalem Institute for Child Development Not yet recruiting
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Jerusalem Institute for Child Development
Investigators
Principal Investigator: David S Wilensky, MD Jerusalem Institute for Child Development

ClinicalTrials.gov Identifier: NCT00318162     History of Changes
Other Study ID Numbers: PDDLDN-HMO-CTIL
First Posted: April 26, 2006    Key Record Dates
Last Update Posted: May 3, 2006
Last Verified: April 2006

Keywords provided by Hadassah Medical Organization:
autism
PDD
LDN
naltrexone

Additional relevant MeSH terms:
Developmental Disabilities
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Autistic Disorder
Neurodevelopmental Disorders
Mental Disorders
Naltrexone
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents